The hyper-activation of transcriptional enhancers in breast cancer

• Published in: Clinical epigenetics 2019-03, Vol.11 (1), p.48-48, Article 48
• Main Authors: Li, Qing-Lan, Wang, Dan-Ya, Ju, Lin-Gao, Yao, Jie, Gao, Chuan, Lei, Pin-Ji, Li, Lian-Yun, Zhao, Xiao-Lu, Wu, Min
• Format: Article
• Language: English
• Subjects: Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer research; Cancer therapies; Chromatin; Chromatin Immunoprecipitation Sequencing; Development and progression; Enhancer Elements, Genetic; Enhancers; Epigenesis, Genetic; Epigenetic inheritance; Epigenetics; Epigenomics; Event-related potentials; Female; Gene expression; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genes; Genetic aspects; Genomes; Genomics; H3K27ac; H3K4me3; H4K8ac; Histone Code; Histones - genetics; Histones - metabolism; Humans; Leukemia; Mammary Neoplasms, Experimental - genetics; Mammary Neoplasms, Experimental - metabolism; Mammary Neoplasms, Experimental - pathology; Mass spectrometry; Mass spectroscopy; Medical research; Metastasis; Peptides; Proteomics; Scientific imaging; Spectroscopy; Studies; Super-enhancer; Transcription (Genetics); Transcription activation; Transcription factors; Transcriptional Activation; Tumorigenesis; Tumors; Up-Regulation; Western blotting
• ISSN: 1868-7075; 1868-7083; 1868-7083; 1868-7075
• DOI: 10.1186/s13148-019-0645-x

Activation of transcription enhancers, especially super-enhancers, is one of the critical epigenetic features of tumorigenesis. However, very few studies have systematically identified the enhancers specific in cancer tissues. Here, we studied the change of histone modifications in MMTV-PyVT breast cancer model, combining mass spectrometry-based proteomics and ChIP-seq-based epigenomics approaches. Some of the proteomic results were confirmed with western blotting and IHC staining. An inhibitor of H3K27ac was applied to study its effect on cancer development. H3K27ac and H4K8ac are elevated in cancer, which was confirmed in patient tissue chips. ChIP-seq revealed that H4K8ac is co-localized with H3K27ac on chromatin, especially on distal enhancers. Epigenomic studies further identified a subgroup of super-enhancers marked by H3K4me3 peaks in the intergenic regions. The H3K4me3-enriched regions enhancers are associated with higher level of H3K27ac and H4K8ac compared with the average level of conventional super-enhancers and are associated with higher transcription level of their adjacent genes. We identified 148 H3K4me3-enriched super-enhancers with higher gene expression in tumor, which may be critical for breast cancer. One inhibitor for p300 and H3K27ac, C646, repressed tumor formation probably through inhibiting Vegfa and other genes. Taken together, our work identifies novel regulators and provides important resource to the genome-wide enhancer studies in breast cancer and raises the possibility of cancer treatment through modulating enhancer activity.